Nordic Luveris Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00553293 |
Recruitment Status :
Completed
First Posted : November 4, 2007
Last Update Posted : November 4, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infertility In Vitro Fertilization | Drug: recombinant luteinizing hormone (Luveris) Drug: recombinant follicle stimulating hormone (Gonal-f) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 526 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Recombinant LH Supplementation to Recombinant FSH During the Final Days of Controlled Ovarian Stimulation for IVF: a Multicentre, Prospective, Randomized, Controlled Trial |
Study Start Date : | August 2003 |
Actual Study Completion Date : | November 2004 |

Arm | Intervention/treatment |
---|---|
Active Comparator: A,1
rFSH + rLH arm
|
Drug: recombinant luteinizing hormone (Luveris)
75 iu/day form cycle day 6
Other Name: Luveris |
Placebo Comparator: A,2
rFSH alone
|
Drug: recombinant follicle stimulating hormone (Gonal-f)
rFSH 150 iu/day
Other Name: Gonal-f |
- Ongoing pregnancy rate per started stimulation cycle [ Time Frame: ultrasound showing ongoing pregnancy ]
- Ongoing pregnancy in subgroups of patients with lo0w serum LH levels [ Time Frame: ultrasound for ongoing pregnancy in subgroups ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 40 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age below 40
- Infertility treatable by IVF or ICSI
- Regular cycles
Exclusion Criteria:
- NA

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00553293
Denmark | |
Anders Nyboe Andersen | |
Copenhagen, Denmark, 2100 |
Principal Investigator: | Anders N Andersen, professor | Fertility Clinic Rigshospitalet |
ClinicalTrials.gov Identifier: | NCT00553293 |
Other Study ID Numbers: |
KF02-035/03 |
First Posted: | November 4, 2007 Key Record Dates |
Last Update Posted: | November 4, 2007 |
Last Verified: | November 2007 |
infertility in vitro fertilization LH supplementation Benefits |
Infertility Hormones Follicle Stimulating Hormone Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |